Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTRA study of SB-007 for Stargardt disease
2024-519535-42-00Phase 2Authorised
- Sponsor
- SpliceBio
- Start
- May 2026
- Modality
- Gene Therapies
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of SB-007 in Fundus Flavimaculatus (FF) (2 arms), sponsored by SpliceBio. Primary endpoint: Safety and tolerability through Week 96. Planned start May 2026; status: authorised.
02
Drugs
SB-007
03
Conditions
Fundus Flavimaculatus (FF)
Beyond the preview
Go deeper on 2024-519535-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519535-42-00.